Abstract | OBJECTIVE: METHODS: A prospectively collected clinical database of 104 consecutive melanoma or RCC patients treated with high-dose IL-2 between 2009 and 2012 was used to compare clinical outcomes and adverse events in patients ≥65 years of age with those of younger patients. RESULTS: There were 22 (21%) patients ≥65 years and 82 (79%) patients <65 years of age. The mean number of IL-2 doses was lower in older patients during cycle 1 of treatment (7.2 vs. 8.6, p = 0.012). There were no other differences in dosing pattern by age group. There was a higher rate of selected cardiac, constitutional, hematologic, metabolic and renal toxicities in younger patients (p < 0.05). Overall, objective responses and survival were not affected by age, though older patients had a higher partial response rate (p = 0.04). CONCLUSIONS:
IL-2 is safe and has comparable therapeutic effectiveness in patients ≥65 years. Age should not be considered a contraindication to treatment with IL-2 in otherwise eligible patients.
|
Authors | James M Clark, Benjamin Kelley, Jill Titze, Henry Fung, John Maciejewski, Sunita Nathan, Elizabeth Rich, Sanjib Basu, Howard L Kaufman |
Journal | Oncology
(Oncology)
Vol. 84
Issue 2
Pg. 123-6
( 2013)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 23235386
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright © 2012 S. Karger AG, Basel. |
Chemical References |
- Antineoplastic Agents
- Interleukin-2
|
Topics |
- Aged
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Renal Cell
(drug therapy, mortality, pathology)
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Humans
- Interleukin-2
(therapeutic use)
- Kidney Neoplasms
(drug therapy, mortality, pathology)
- Male
- Melanoma
(drug therapy, mortality, secondary)
- Middle Aged
- Neoplasm Staging
- Prognosis
- Prospective Studies
- Survival Rate
|